Financial Performance - For the fiscal year ending December 31, 2024, the group's revenue increased by approximately 155.4% to about HKD 166.2 million, compared to HKD 65.0 million in the fiscal year 2023[5] - The group's gross profit for the fiscal year 2024 rose by approximately 2.0% to about HKD 57.4 million, compared to HKD 56.3 million in the fiscal year 2023[5] - The group recorded a post-tax loss of approximately HKD 34.8 million for the fiscal year 2024, compared to a post-tax profit of approximately HKD 2.5 million in the fiscal year 2023[5] - Total revenue for the year ended December 31, 2024, reached HKD 166,181,000, a significant increase from HKD 64,989,000 in 2023, representing a growth of approximately 156%[34] - The company reported a pre-tax profit of HKD 4,745,000 for the year ended December 31, 2024, compared to a loss in the previous year[34] - The group reported a net loss of approximately HKD 34.80 million in fiscal year 2024, compared to a profit of HKD 2.52 million in fiscal year 2023[69] Assets and Liabilities - The group's net assets decreased by 7.0% to HKD 400.1 million in the fiscal year 2024, down from HKD 430.5 million in 2023[5] - The total liabilities for the group increased significantly, with current liabilities totaling HKD 121.7 million in 2024, compared to HKD 73.3 million in 2023[10] - The group's cash and cash equivalents decreased to HKD 47.8 million in 2024 from HKD 81.1 million in 2023[10] - The total assets of the company as of December 31, 2024, were HKD 525,631,000, an increase from HKD 509,254,000 in 2023[29] - As of December 31, 2024, the group recorded net current assets of approximately HKD 372,047,000, an increase from HKD 250,127,000 in the fiscal year 2023[89] Revenue Segmentation - For the fiscal year ending December 31, 2024, the company reported segment revenues of HKD 142,016,000 from longevity science, HKD 24,165,000 from lending and financial consulting, totaling HKD 166,181,000[25] - Revenue from health and medical product sales was HKD 102,411,000 in 2024, compared to HKD 4,447,000 in 2023, indicating a substantial increase[34] - Major clients contributed significantly to revenue, with Client B generating HKD 65,650,000 and Client C contributing HKD 32,900,000 in 2024[32] - The lending and financial consulting segment recorded revenue of approximately HKD 24.17 million in fiscal year 2024, down from HKD 33.66 million in fiscal year 2023[71] Operational Developments - The company plans to expand its longevity science business by starting sales and distribution of longevity wine in 2024[22] - The company is actively expanding its longevity management services, establishing centers in major global cities like Hong Kong and Shenzhen, enhancing brand influence and service quality[56] - The strategic shift towards supply chain finance in the longevity science sector has improved operational quality and efficiency, reducing business risks[54] - The company plans to increase R&D investment and promote technological innovation in longevity science, aiming to solidify its position as a global leader by 2025[56] Challenges and Risks - The company is navigating challenges in the lending and financial consulting business due to a sluggish real estate market and regulatory changes impacting mortgage demand[59][60] - A strategic partnership with law firms has been initiated to expedite the recovery of overdue loans, involving significant operational efforts[62] - The expected credit loss model led to a significant impairment loss of HKD 15,938,000 in 2024, compared to a reversal of HKD 5,699,000 in 2023[36] Shareholder Returns and Dividends - The group did not recommend a final dividend for the fiscal year 2024, consistent with the fiscal year 2023[5] - The basic and diluted loss per share attributable to the owners of the company for the year ending December 31, 2024, is (HKD 34,726) thousand, compared to a profit of HKD 2,313 thousand in 2023[43] - The board of directors remains committed to shareholder returns, with plans to increase dividends by 10% in the next fiscal year[124] Corporate Governance - The audit committee has reviewed and approved the consolidated financial statements for the fiscal year 2024, ensuring compliance with applicable accounting standards and regulations[119] - The company has adopted the corporate governance code and has complied with applicable provisions during the fiscal year 2024[116] Future Outlook - The company is optimistic about the growth potential of its longevity science business despite recent challenges, including a significant marketing cost of HKD 9,000,000 related to NMN products[82] - The company is exploring potential acquisitions to strengthen its market position, with a budget of $200 million allocated for this purpose[124] - The company projects a revenue guidance of $500 million for Q2 2025, reflecting a 20% growth from Q1 2025[124]
中基长寿科学(00767) - 2024 - 年度业绩